DE69721235T2 - Verbesserungen an (oder im bezug auf) kontrastmittel - Google Patents
Verbesserungen an (oder im bezug auf) kontrastmittel Download PDFInfo
- Publication number
- DE69721235T2 DE69721235T2 DE69721235T DE69721235T DE69721235T2 DE 69721235 T2 DE69721235 T2 DE 69721235T2 DE 69721235 T DE69721235 T DE 69721235T DE 69721235 T DE69721235 T DE 69721235T DE 69721235 T2 DE69721235 T2 DE 69721235T2
- Authority
- DE
- Germany
- Prior art keywords
- gas
- phospholipid
- matrix
- microbubbles
- dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003904 phospholipids Chemical class 0.000 claims description 67
- 239000002872 contrast media Substances 0.000 claims description 65
- 239000006185 dispersion Substances 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 33
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 22
- 229940039231 contrast media Drugs 0.000 claims description 20
- 229950003332 perflubutane Drugs 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 16
- 239000002961 echo contrast media Substances 0.000 claims description 14
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 13
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 13
- 229910018503 SF6 Inorganic materials 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 239000002577 cryoprotective agent Substances 0.000 claims description 9
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 150000002430 hydrocarbons Chemical class 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000008365 aqueous carrier Substances 0.000 claims description 6
- 150000008106 phosphatidylserines Chemical class 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 5
- 210000003934 vacuole Anatomy 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000007789 gas Substances 0.000 description 115
- 239000000047 product Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000003570 air Substances 0.000 description 23
- 238000004108 freeze drying Methods 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 19
- 238000009826 distribution Methods 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000002604 ultrasonography Methods 0.000 description 13
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 12
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- -1 polyoxyethylene Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229960003853 ultrasound contrast media Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000959 cryoprotective effect Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 125000001924 fatty-acyl group Chemical group 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- QIYZKVMAFMDRTP-UHFFFAOYSA-N pentafluoro(trifluoromethyl)-$l^{6}-sulfane Chemical compound FC(F)(F)S(F)(F)(F)(F)F QIYZKVMAFMDRTP-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 238000012285 ultrasound imaging Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- ABQLAMJAQZFPJI-UHFFFAOYSA-N 3-heptyloxolan-2-one Chemical compound CCCCCCCC1CCOC1=O ABQLAMJAQZFPJI-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000183024 Populus tremula Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000005548 dental material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical class FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WSJULBMCKQTTIG-OWOJBTEDSA-N (e)-1,1,1,2,3,4,4,4-octafluorobut-2-ene Chemical compound FC(F)(F)C(/F)=C(\F)C(F)(F)F WSJULBMCKQTTIG-OWOJBTEDSA-N 0.000 description 1
- COQIQRBKEGPRSG-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(F)(C(F)(F)F)C(F)(F)F COQIQRBKEGPRSG-UHFFFAOYSA-N 0.000 description 1
- FNVLGCVAWPSVSK-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7-tetradecafluorocycloheptane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F FNVLGCVAWPSVSK-UHFFFAOYSA-N 0.000 description 1
- RKIMETXDACNTIE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorocyclohexane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F RKIMETXDACNTIE-UHFFFAOYSA-N 0.000 description 1
- QIROQPWSJUXOJC-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-(trifluoromethyl)cyclohexane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F QIROQPWSJUXOJC-UHFFFAOYSA-N 0.000 description 1
- PWMJXZJISGDARB-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5-decafluorocyclopentane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F PWMJXZJISGDARB-UHFFFAOYSA-N 0.000 description 1
- BCNXQFASJTYKDJ-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5-nonafluoro-5-(trifluoromethyl)cyclopentane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F BCNXQFASJTYKDJ-UHFFFAOYSA-N 0.000 description 1
- CIWUYWQUYMZILR-UHFFFAOYSA-N 1,1,2,2,3,3,4,4-octafluoro-5,5-bis(trifluoromethyl)cyclopentane Chemical class FC(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C1(F)F CIWUYWQUYMZILR-UHFFFAOYSA-N 0.000 description 1
- ZVXOHSHODRJTCP-UHFFFAOYSA-N 1,1,2,2,3,3,4-heptafluoro-4-(trifluoromethyl)cyclobutane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C1(F)F ZVXOHSHODRJTCP-UHFFFAOYSA-N 0.000 description 1
- TXGPGHBYAPBDAG-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluoro-4,4-bis(trifluoromethyl)cyclobutane Chemical compound FC(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C1(F)F TXGPGHBYAPBDAG-UHFFFAOYSA-N 0.000 description 1
- YUFJLVUCHXMKKM-UHFFFAOYSA-N 1,1,2,2,3-pentafluoro-3,4,4-tris(trifluoromethyl)cyclobutane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C(F)(F)F YUFJLVUCHXMKKM-UHFFFAOYSA-N 0.000 description 1
- ZVJOQYFQSQJDDX-UHFFFAOYSA-N 1,1,2,3,3,4,4,4-octafluorobut-1-ene Chemical class FC(F)=C(F)C(F)(F)C(F)(F)F ZVJOQYFQSQJDDX-UHFFFAOYSA-N 0.000 description 1
- LGPPATCNSOSOQH-UHFFFAOYSA-N 1,1,2,3,4,4-hexafluorobuta-1,3-diene Chemical compound FC(F)=C(F)C(F)=C(F)F LGPPATCNSOSOQH-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 108010056388 Albunex Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 239000004340 Chloropentafluoroethane Substances 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- MEXUFEQDCXZEON-UHFFFAOYSA-N bromochlorodifluoromethane Chemical compound FC(F)(Cl)Br MEXUFEQDCXZEON-UHFFFAOYSA-N 0.000 description 1
- RJCQBQGAPKAMLL-UHFFFAOYSA-N bromotrifluoromethane Chemical compound FC(F)(F)Br RJCQBQGAPKAMLL-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019406 chloropentafluoroethane Nutrition 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical compound FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- JVKAWJASTRPFQY-UHFFFAOYSA-N n-(2-aminoethyl)hydroxylamine Chemical compound NCCNO JVKAWJASTRPFQY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- LGUZHRODIJCVOC-UHFFFAOYSA-N perfluoroheptane Chemical class FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F LGUZHRODIJCVOC-UHFFFAOYSA-N 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical class FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- QTJXVIKNLHZIKL-UHFFFAOYSA-N sulfur difluoride Chemical class FSF QTJXVIKNLHZIKL-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9603466 | 1996-02-19 | ||
| GBGB9603466.5A GB9603466D0 (en) | 1996-02-19 | 1996-02-19 | Improvements in or relating to contrast agents |
| GB9611894 | 1996-06-07 | ||
| GBGB9611894.8A GB9611894D0 (en) | 1996-06-07 | 1996-06-07 | Improvements in or relating to contrast agents |
| GB9625663 | 1996-12-11 | ||
| GBGB9625663.1A GB9625663D0 (en) | 1996-12-11 | 1996-12-11 | Improvements in or relating to contrast agents |
| PCT/GB1997/000459 WO1997029783A1 (en) | 1996-02-19 | 1997-02-19 | Improvements in or relating to contrast agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69721235D1 DE69721235D1 (de) | 2003-05-28 |
| DE69721235T2 true DE69721235T2 (de) | 2004-02-05 |
Family
ID=27268137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69721235T Expired - Lifetime DE69721235T2 (de) | 1996-02-19 | 1997-02-19 | Verbesserungen an (oder im bezug auf) kontrastmittel |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6221337B1 (enExample) |
| EP (2) | EP1331013A3 (enExample) |
| JP (1) | JP4418033B2 (enExample) |
| KR (1) | KR100500334B1 (enExample) |
| CN (1) | CN1278740C (enExample) |
| AP (1) | AP890A (enExample) |
| AT (1) | ATE238072T1 (enExample) |
| AU (1) | AU726503B2 (enExample) |
| BG (1) | BG102758A (enExample) |
| CA (1) | CA2246779C (enExample) |
| CZ (1) | CZ293986B6 (enExample) |
| DE (1) | DE69721235T2 (enExample) |
| EA (1) | EA001135B1 (enExample) |
| EE (1) | EE04224B1 (enExample) |
| ES (1) | ES2197986T3 (enExample) |
| HU (1) | HU229090B1 (enExample) |
| IL (1) | IL125748A (enExample) |
| NZ (1) | NZ331509A (enExample) |
| OA (1) | OA10839A (enExample) |
| PL (1) | PL328406A1 (enExample) |
| PT (1) | PT881915E (enExample) |
| SK (1) | SK284200B6 (enExample) |
| TR (1) | TR199801613T2 (enExample) |
| WO (1) | WO1997029783A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784367B2 (en) * | 1996-08-02 | 2006-03-16 | Ge Healthcare As | Improvements in or relating to contrast agents |
| CA2262908A1 (en) * | 1996-08-02 | 1998-02-12 | David Johnson | Contrast agents for ultrasound imaging of the liver |
| ATE252916T1 (de) * | 1997-08-12 | 2003-11-15 | Bracco Research Sa | Verabreichbare formulierugen und ihre anwendung in mri |
| GB9717476D0 (en) * | 1997-08-18 | 1997-10-22 | Nycomed Imaging As | Process |
| GB9717589D0 (en) * | 1997-08-19 | 1997-10-22 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| GB9717588D0 (en) * | 1997-08-19 | 1997-10-22 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| GB9717542D0 (en) * | 1997-08-19 | 1997-10-22 | Nycomed Imaging As | Process |
| GB9726773D0 (en) * | 1997-12-18 | 1998-02-18 | Nycomed Imaging As | Improvements in or relating to ultrasonagraphy |
| ATE265525T1 (de) * | 1998-04-28 | 2004-05-15 | Amersham Health As | Verbesserung von trennungsverfahren |
| GB9813568D0 (en) | 1998-06-23 | 1998-08-19 | Nycomed Imaging As | Improvements in or relating to cardiac imaging |
| US6514209B1 (en) | 1999-06-07 | 2003-02-04 | Drexel University | Method of enhancing ultrasonic techniques via measurement of ultraharmonic signals |
| US20030103960A1 (en) * | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
| AU2001266696A1 (en) | 2000-06-02 | 2001-12-11 | Bracco Research Usa | Compounds for targeting endothelial cells |
| NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
| KR100373712B1 (ko) * | 2000-12-23 | 2003-02-25 | 사회복지법인삼성생명공익재단(삼성서울병원) | 초음파 조영제 및 그의 제조방법 |
| US6984373B2 (en) | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
| WO2002080774A2 (en) | 2001-04-06 | 2002-10-17 | Bracco Research S.A. | Method for improved measurement of local physical parameters in afluid-filled cavity |
| JP2005522422A (ja) * | 2002-02-01 | 2005-07-28 | シモダ、バイオテック（プロプライエタリー）リミテッド | 医薬組成物 |
| EP2014310B8 (en) | 2002-03-01 | 2012-12-26 | Dyax Corp. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| NO20024755D0 (no) * | 2002-10-03 | 2002-10-03 | Amersham Health As | Metode |
| KR20050072496A (ko) | 2002-11-29 | 2005-07-11 | 아머샴 헬스 에이에스 | 초음파 촬영 방법 |
| US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| DE602004029010D1 (de) * | 2003-02-04 | 2010-10-21 | Bracco Suisse Sa | Ultraschall kontrastmittel und verfahren zur erstellung |
| ES2396368T3 (es) | 2003-03-03 | 2013-02-21 | Dyax Corporation | Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos |
| EP1643972A4 (en) * | 2003-06-27 | 2010-01-20 | Smithkline Beecham Corp | STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD |
| US20050019379A1 (en) | 2003-07-22 | 2005-01-27 | Kimberly-Clark Worldwide, Inc. | Wipe and methods for improving skin health |
| NO20035401D0 (no) * | 2003-12-04 | 2003-12-04 | Amersham Health As | Metode |
| CN1897978B (zh) * | 2003-12-22 | 2011-11-23 | 博莱科瑞士股份有限公司 | 具有用于反差成像的活性组分的充气微囊组件 |
| AU2004308756B2 (en) * | 2003-12-22 | 2010-06-24 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
| US7025726B2 (en) | 2004-01-22 | 2006-04-11 | The Regents Of The University Of Nebraska | Detection of endothelial dysfunction by ultrasonic imaging |
| CN101005858A (zh) | 2004-08-18 | 2007-07-25 | 伯拉考开发股份有限公司 | 用于反差成像的充气微泡组合物 |
| WO2006044997A2 (en) * | 2004-10-15 | 2006-04-27 | The Trustees Of Columbia University In The City Of New York | System and method for localized measurement and imaging of viscosity of tissues |
| WO2006044996A2 (en) * | 2004-10-15 | 2006-04-27 | The Trustees Of Columbia University In The City Of New York | System and method for automated boundary detection of body structures |
| CN100574809C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用氟碳乳剂类助剂及其应用 |
| CN100427142C (zh) * | 2005-01-10 | 2008-10-22 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
| CN100574811C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用微粒类助剂及其应用 |
| US10687785B2 (en) | 2005-05-12 | 2020-06-23 | The Trustees Of Columbia Univeristy In The City Of New York | System and method for electromechanical activation of arrhythmias |
| WO2007035721A2 (en) * | 2005-09-19 | 2007-03-29 | The Trustees Of Columbia University In The City Of New York | Ultrasound method to open blood brain barrier |
| MX2008007321A (es) | 2005-12-09 | 2008-09-30 | Bracco Int Bv | Conjugados fosfolipido de vector dirigido. |
| EP1797919A1 (en) | 2005-12-16 | 2007-06-20 | Bracco Research S.A. | Liquid transfer device for medical dispensing containers |
| DOP2007000020A (es) | 2006-01-31 | 2007-09-15 | Bayer Schering Pharma Ag | Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias |
| JP5154554B2 (ja) | 2006-08-01 | 2013-02-27 | ボストン サイエンティフィック サイムド，インコーポレイテッド | 非線形イメージングのためのパルスインバージョンシーケンス |
| US8150128B2 (en) * | 2006-08-30 | 2012-04-03 | The Trustees Of Columbia University In The City Of New York | Systems and method for composite elastography and wave imaging |
| JP5420410B2 (ja) | 2006-09-05 | 2014-02-19 | ブラッコ・シュイス・ソシエテ・アノニム | ポリマー修飾脂質を含むガス封入微小胞 |
| EP2005970A1 (de) | 2007-06-22 | 2008-12-24 | Berlin Science Partners GmbH i.V. | Bildgebende Diagnostik durch Kombination von Kontrastmitteln |
| JP2010005512A (ja) * | 2008-06-25 | 2010-01-14 | Kao Corp | 微細気泡前駆体組成物 |
| GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
| WO2010014977A1 (en) | 2008-08-01 | 2010-02-04 | The Trustees Of Columbia University In The City Of New York | Systems and methods for matching and imaging tissue characteristics |
| WO2010030819A1 (en) | 2008-09-10 | 2010-03-18 | The Trustees Of Columbia University In The City Of New York | Systems and methods for opening a tissue |
| EP2334239A4 (en) * | 2008-09-10 | 2011-10-19 | Univ Columbia | INSULATION OF MICROBUMS OF A SPECIFIC SIZE OF POLYDISPERSE MICROBUBBLES |
| US10058837B2 (en) | 2009-08-28 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
| EP2477550A4 (en) * | 2009-09-15 | 2013-12-04 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR MICROBUBBLES |
| WO2011035254A1 (en) * | 2009-09-21 | 2011-03-24 | Drexel University | Stabilized ultrasound contrast agent |
| EP2480144B1 (en) | 2009-09-21 | 2024-03-06 | The Trustees of Columbia University in the City of New York | Systems for opening of a tissue barrier |
| US8834846B2 (en) | 2010-05-06 | 2014-09-16 | Bruker Biospin Corporation | Fluorescent NIRF activatable probes for disease detection |
| US9265483B2 (en) | 2010-08-06 | 2016-02-23 | The Trustees Of Columbia University In The City Of New York | Medical imaging contrast devices, methods, and systems |
| WO2012136813A2 (en) | 2011-04-07 | 2012-10-11 | Universitetet I Oslo | Agents for medical radar diagnosis |
| WO2012162664A1 (en) | 2011-05-26 | 2012-11-29 | The Trustees Of Columbia University In The City Of New York | Systems and methods for opening of a tissue barrier in primates |
| AU2013255952B2 (en) | 2012-04-30 | 2018-04-12 | Ge Healthcare As | Method for filling a container with a foamable composition |
| JP6420761B2 (ja) | 2012-06-26 | 2018-11-07 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 気体マイクロバブルを含む組成物の調製 |
| WO2014059170A1 (en) | 2012-10-10 | 2014-04-17 | The Trustees Of Columbia University In The City Of New York | Systems and methods for mechanical mapping of cardiac rhythm |
| WO2014096165A2 (en) | 2012-12-21 | 2014-06-26 | Bracco Suisse Sa | Gas-filled microvesicles |
| WO2014142926A1 (en) | 2013-03-14 | 2014-09-18 | Empire Technology Development Llc | Identification of surgical smoke |
| CN105050614B (zh) | 2013-03-15 | 2019-04-05 | 加利福尼亚大学董事会 | 刺激胆固醇流出的具有降低的毒性的肽 |
| US9247921B2 (en) | 2013-06-07 | 2016-02-02 | The Trustees Of Columbia University In The City Of New York | Systems and methods of high frame rate streaming for treatment monitoring |
| US10322178B2 (en) | 2013-08-09 | 2019-06-18 | The Trustees Of Columbia University In The City Of New York | Systems and methods for targeted drug delivery |
| US10028723B2 (en) | 2013-09-03 | 2018-07-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for real-time, transcranial monitoring of blood-brain barrier opening |
| GB201405735D0 (en) * | 2014-03-31 | 2014-05-14 | Ge Healthcare As | Ultrasound precursor preparation method |
| US10682429B2 (en) | 2014-12-18 | 2020-06-16 | Bracco Suisse S.A. | Targeted gas-filled microvesicles formulation |
| US10688199B2 (en) * | 2015-06-10 | 2020-06-23 | Teikyo University | Theranostic bubble preparation (TB), and method for using same |
| CN107233583B (zh) * | 2016-03-29 | 2020-04-24 | 北京飞锐达医疗科技有限公司 | 一种具有超长持续时间的超声造影剂及其制备方法 |
| GB201821049D0 (en) * | 2018-12-21 | 2019-02-06 | Ge Healthcare As | Ultrasound contrast agent and methods for use therof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| IN172208B (enExample) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| DE4100470A1 (de) * | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echokontrastmittel |
| GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| DE4328642A1 (de) * | 1993-08-26 | 1995-03-02 | Byk Gulden Lomberg Chem Fab | Ultraschallkontrastmittel |
| GB9511488D0 (en) * | 1995-06-07 | 1995-08-02 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
-
1997
- 1997-02-19 EA EA199800745A patent/EA001135B1/ru active IP Right Revival
- 1997-02-19 EE EE9800249A patent/EE04224B1/xx not_active IP Right Cessation
- 1997-02-19 CA CA002246779A patent/CA2246779C/en not_active Expired - Lifetime
- 1997-02-19 AP APAP/P/1998/001319A patent/AP890A/en active
- 1997-02-19 CN CNB971931895A patent/CN1278740C/zh not_active Expired - Lifetime
- 1997-02-19 TR TR1998/01613T patent/TR199801613T2/xx unknown
- 1997-02-19 HU HU9900813A patent/HU229090B1/hu unknown
- 1997-02-19 PL PL97328406A patent/PL328406A1/xx unknown
- 1997-02-19 AU AU18847/97A patent/AU726503B2/en not_active Ceased
- 1997-02-19 JP JP52913197A patent/JP4418033B2/ja not_active Expired - Lifetime
- 1997-02-19 IL IL12574897A patent/IL125748A/en not_active IP Right Cessation
- 1997-02-19 DE DE69721235T patent/DE69721235T2/de not_active Expired - Lifetime
- 1997-02-19 NZ NZ331509A patent/NZ331509A/xx unknown
- 1997-02-19 KR KR10-1998-0706415A patent/KR100500334B1/ko not_active Expired - Lifetime
- 1997-02-19 EP EP03008699A patent/EP1331013A3/en not_active Withdrawn
- 1997-02-19 EP EP97905222A patent/EP0881915B1/en not_active Expired - Lifetime
- 1997-02-19 WO PCT/GB1997/000459 patent/WO1997029783A1/en not_active Ceased
- 1997-02-19 CZ CZ19982625A patent/CZ293986B6/cs not_active IP Right Cessation
- 1997-02-19 SK SK1126-98A patent/SK284200B6/sk unknown
- 1997-02-19 PT PT97905222T patent/PT881915E/pt unknown
- 1997-02-19 ES ES97905222T patent/ES2197986T3/es not_active Expired - Lifetime
- 1997-02-19 AT AT97905222T patent/ATE238072T1/de not_active IP Right Cessation
-
1998
- 1998-08-14 OA OA9800144A patent/OA10839A/en unknown
- 1998-08-19 US US09/136,410 patent/US6221337B1/en not_active Expired - Lifetime
- 1998-09-09 BG BG102758A patent/BG102758A/xx unknown
-
2001
- 2001-02-15 US US09/783,793 patent/US20010010811A1/en not_active Abandoned
-
2002
- 2002-11-22 US US10/302,800 patent/US20030202942A1/en not_active Abandoned
-
2005
- 2005-03-04 US US11/073,027 patent/US20050201942A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69721235T2 (de) | Verbesserungen an (oder im bezug auf) kontrastmittel | |
| DE69720979T2 (de) | Thermostabilisiertes kontrastmittel | |
| DE69632907T2 (de) | Neue zusammensetzungen von lipiden und stabilisierenden materialen | |
| DE69621015T2 (de) | Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind | |
| DE69432358T2 (de) | Gashaltige mikrosphären zur topischen und subkutanen anwendung | |
| DE69231950T3 (de) | Gasgefüllte liposome als ultraschall-kontrastmittel | |
| DE69111719T3 (de) | Stabile mikroblasensuspensionen zur injektion in lebewesen. | |
| DE69527194T2 (de) | Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel | |
| DE69522670T2 (de) | Gefrorenes echo, verfahren zur speicherung von ultraschall-gassuspensionen | |
| DE69425136T2 (de) | Verbesserungen an und in beziehung zu kontrastmitteln | |
| DE69819309T2 (de) | Verabreichbare formulierugen und ihre anwendung in mri | |
| CZ28999A3 (cs) | Použití kontrastního prostředku | |
| DE29522119U1 (de) | Oberwellenultraschallabbildung mit Mikroblasen | |
| DE60006683T2 (de) | Methode um ein gasenthaltendes konstrastmittel mit einer spülflüssigkeit zu mischen vor der verabrechnung in einer kontinuierlichen infustion | |
| DE60111917T2 (de) | Lyophilisierbares Kontrastmittel, gasgefüllte Mikrobläschen enthaltend | |
| US6217850B1 (en) | Method of making lyophilized microbubble compositions useful as contrast agents | |
| EP1007103A2 (en) | Process for preparation of lyophilised contrast agents | |
| HK1014872B (en) | Improvements in or relating to contrast agents | |
| NO318875B1 (no) | Ultralydkontrastmiddel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: GE HEALTHCARE AS, OSLO, NO |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |
|
| R082 | Change of representative |
Ref document number: 881915 Country of ref document: EP Representative=s name: J D REYNOLDS & CO., GB |